This study assesses a potentially novel combination of CDK4/6 inhibition with chemotherapy in ovarian cancer and demonstrates the safety and promising efficacy of sequencing this class of drugs with standard-of-care chemotherapy in ovarian cancer. This evidence concerns the gene CDK4 and ovarian cancer.